Sevelamer
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hyperphosphatemia in CKD on dialysis — control of serum phosphorus | Adults | Monotherapy or part of CKD-MBD regimen | FDA Approved |
| Hyperphosphatemia in CKD on dialysis — pediatric | Children ≥6 years | Monotherapy or part of CKD-MBD regimen | FDA Approved |
Sevelamer is a non-absorbed, calcium-free, metal-free phosphate binder indicated specifically for dialysis patients with CKD. It binds dietary phosphate in the gastrointestinal tract, preventing absorption and thereby lowering serum phosphorus levels. Sevelamer is favoured over calcium-based binders when hypercalcaemia, adynamic bone disease, or progressive vascular calcification is a concern. Two salt forms exist: sevelamer carbonate (Renvela) is the current standard, having replaced sevelamer hydrochloride (Renagel) because the carbonate counterion avoids the metabolic acidosis risk associated with the chloride salt.
Hyperphosphatemia in CKD not on dialysis (pre-dialysis CKD stages 3–5) (evidence: moderate) — KDIGO 2017 guidelines suggest phosphate-lowering therapy in progressive hyperphosphatemia even before dialysis initiation. Sevelamer has been studied in this population and is used clinically, though the FDA indication specifies dialysis patients.
Reduction of LDL cholesterol in CKD (evidence: low) — Sevelamer binds bile acids in addition to phosphate, producing a 15–31% reduction in total and LDL cholesterol in clinical trials. This is not an approved indication but is a recognized pleiotropic benefit.
Dosing
Adults — Phosphate Binder–Naïve Patients
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Serum phosphorus >5.5 and <7.5 mg/dL | 0.8 g TID with meals | Titrate by 0.8 g/meal q2wk | 14 g/day (max studied) | Average clinical dose ~7.2 g/day Take with meals; do not crush or break tablets |
| Serum phosphorus ≥7.5 mg/dL | 1.6 g TID with meals | Titrate by 0.8 g/meal q2wk | 14 g/day (max studied) | Higher starting dose for severe hyperphosphatemia Target: serum phosphorus 3.5–5.5 mg/dL (KDOQI) |
| Switching from calcium acetate 667 mg | 1 calcium acetate tablet per meal = 0.8 g sevelamer per meal; 2 tablets = 1.6 g; 3 tablets = 2.4 g | Approximate mg-for-mg conversion Further titration likely needed to maintain phosphorus control | ||
| Switching from sevelamer HCl (Renagel) | Same dose in grams (gram-for-gram conversion) | Equivalent phosphate-binding capacity Carbonate salt avoids metabolic acidosis risk | ||
Pediatric Dosing (≥6 years, by Body Surface Area)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| BSA ≥0.75 to <1.2 m² | 0.8 g TID with meals | Titrate by 0.4 g/meal q2wk | Per phosphorus target | Titrate q2wk for first 6 weeks, then q4wk |
| BSA ≥1.2 m² | 1.6 g TID with meals | Titrate by 0.8 g/meal q2wk | Per phosphorus target | Not studied in children <6 years Powder formulation available for children who cannot swallow tablets |
At the average maintenance dose of 7.2 g/day, patients typically take nine 800 mg tablets daily (three with each meal). High pill burden is a major adherence challenge with sevelamer. The powder formulation (0.8 g or 2.4 g packets suspended in water) offers an alternative for patients who struggle with the number of tablets, though compliance with the suspension preparation instructions is essential — it must be stirred vigorously, consumed within 30 minutes, and never heated.
Pharmacology
Mechanism of Action
Sevelamer is a non-absorbed, cross-linked polymeric amine (poly(allylamine)) that operates entirely within the gastrointestinal lumen. In the acidic environment of the stomach and proximal intestine, the amine groups on the polymer backbone become protonated, creating a polycationic resin. These protonated amines bind dietary phosphate ions through a combination of ionic interactions and hydrogen bonding. The phosphate–polymer complex passes through the GI tract without being absorbed and is eliminated in the faeces, effectively reducing intestinal phosphate absorption and thereby lowering serum phosphorus levels. Unlike calcium-based binders, sevelamer does not contribute exogenous calcium load, making it advantageous in patients at risk for hypercalcaemia or vascular calcification. As an additional pharmacodynamic property, sevelamer binds bile acids in the intestinal lumen (similar to bile acid sequestrants), which leads to upregulation of hepatic LDL receptors and a clinically measurable 15–31% reduction in total and LDL cholesterol.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Not absorbed systemically; confirmed by ¹&sup4;C mass balance study showing no systemic radioactivity | No systemic toxicity expected; drug interactions occur only in the GI lumen |
| Distribution | Not applicable — remains in the GI lumen | No dose adjustment needed for renal or hepatic impairment |
| Metabolism | Not metabolized; the polymer is chemically stable in the GI environment | No CYP enzyme involvement; no metabolic drug interactions |
| Elimination | Eliminated entirely in faeces as phosphate-bound complex | Efficacy depends on taking the drug with meals when dietary phosphate is present in the gut |
In preclinical studies, sevelamer reduced levels of fat-soluble vitamins (D, E, K) and folic acid at 6–10 times the human dose. In a one-year clinical trial, 25-hydroxyvitamin D levels fell modestly from 39 ± 22 to 34 ± 22 ng/mL (p<0.01) with sevelamer treatment. Most patients (~75%) in clinical trials were receiving vitamin supplements. Clinicians should ensure adequate supplementation and monitor vitamin levels periodically.
Side Effects
Adverse reaction data are primarily from a 52-week, parallel-design study of sevelamer hydrochloride (N=99) versus active comparator (N=101) in hemodialysis patients. Since sevelamer carbonate contains the same active moiety, the adverse event profiles are expected to be similar (FDA PI).
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Vomiting | 22% | Most frequent adverse reaction; may improve with dose titration and taking medication with sufficient food |
| Nausea | 20% | Common across phosphate binder trials; may contribute to poor nutritional intake in dialysis patients |
| Diarrhea | 19% | May be related to osmotic effects of unabsorbed polymer; typically dose-dependent |
| Dyspepsia | 16% | Epigastric discomfort common; taking with adequate food volume may help |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Abdominal pain | 9% | Evaluate for GI complications if severe or persistent |
| Flatulence | 8% | Related to GI effects of the polymer; generally mild |
| Constipation | 8% | Monitor closely; severe constipation can progress to fecal impaction or obstruction |
| Peritonitis (PD patients) | 8% | Observed in peritoneal dialysis trial (8/99 sevelamer vs 2/46 control); may reflect underlying PD risk rather than drug effect |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Bowel obstruction / ileus | Rare (postmarketing) | Variable; higher risk with severe constipation | Discontinue sevelamer; surgical consultation; supportive care |
| GI ulceration / bleeding / necrosis / perforation | Rare (postmarketing) | Variable | Discontinue; endoscopy/surgical evaluation; may resolve upon drug cessation |
| Dysphagia / esophageal tablet retention | Rare (postmarketing) | Any time; risk higher with swallowing disorders | Switch to powder/suspension formulation; evaluate swallowing function |
| Fecal impaction | Uncommon (postmarketing) | Gradual; preceded by worsening constipation | Aggressive bowel regimen; consider dose reduction or alternative binder; disimpaction if needed |
GI complaints are the most common reason for sevelamer discontinuation. Strategies to improve tolerance include gradual dose titration, ensuring tablets are swallowed whole with adequate fluid and food, and switching between tablet and powder formulations. Patients should be instructed to report new-onset or worsening constipation or bloody stools promptly, as these may herald serious GI complications requiring drug cessation.
Drug Interactions
Sevelamer is not absorbed and does not interact with CYP enzymes. All clinically relevant interactions occur through intraluminal binding — sevelamer can physically adsorb co-administered oral drugs in the GI tract, reducing their bioavailability. The magnitude of interaction depends on drug physicochemical properties and timing relative to sevelamer dosing.
Monitoring
- Serum PhosphorusEvery 2 weeks during titration; monthly once stable
RoutineTarget: 3.5–5.5 mg/dL (KDOQI for dialysis). Basis for all dose adjustments. Also check calcium–phosphorus product. - Serum CalciumMonthly
RoutineSevelamer does not directly affect calcium, but it is monitored as part of CKD-MBD assessment. Advantage over calcium-based binders: no exogenous calcium load. - iPTHEvery 3–6 months
RoutineKDIGO target: 2–9 times upper normal limit for dialysis patients. Sevelamer has less PTH-suppressing effect than calcium-based binders. - Serum BicarbonateBaseline; periodically if on HCl salt
Trigger-basedSevelamer HCl (Renagel) can worsen metabolic acidosis by releasing chloride; the carbonate salt (Renvela) avoids this. Switch to carbonate if acidosis develops. - 25-OH Vitamin DBaseline; then annually
RoutineSevelamer may reduce fat-soluble vitamin absorption. In a 1-year trial, 25-OH vitamin D dropped from 39 to 34 ng/mL (p<0.01). Ensure vitamin D supplementation. - Lipid ProfileBaseline; then periodically
RoutineSevelamer reduces total and LDL cholesterol by 15–31% via bile acid binding. This is a secondary benefit; HDL and triglycerides are typically unaffected. - GI SymptomsAt every visit
RoutineAsk about constipation, abdominal pain, blood in stool, and swallowing difficulty at each encounter. These symptoms may precede serious GI complications.
Contraindications & Cautions
Absolute Contraindications
- Bowel obstruction — sevelamer tablets may worsen or cause complete obstruction; patients with known obstruction must not receive sevelamer in any formulation.
- Known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or any excipient — hypersensitivity reactions including pruritus and rash have been reported in postmarketing surveillance.
Relative Contraindications (Specialist Input Recommended)
- Dysphagia or swallowing disorders — cases of esophageal tablet retention requiring hospitalization have been reported. Consider the powder/suspension formulation for these patients.
- Severe GI motility disorders or severe constipation — these patients were excluded from clinical trials; sevelamer may worsen constipation and lead to fecal impaction or obstruction.
- Major GI tract surgery — patients with extensive GI resection may have altered motility and increased obstruction risk; these patients were excluded from trials.
Use with Caution
- Patients taking medications with narrow therapeutic indices — sevelamer may bind co-administered drugs in the GI lumen; separate dosing and/or monitor levels (e.g., cyclosporine, tacrolimus, levothyroxine).
- Patients with existing vitamin deficiencies — sevelamer may reduce absorption of fat-soluble vitamins (A, D, E, K) and folic acid; ensure supplementation.
- Pregnancy — while sevelamer is not absorbed, its potential to reduce maternal absorption of fat-soluble vitamins and folic acid warrants supplementation and monitoring.
Serious cases of dysphagia, bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have been associated with sevelamer use, some requiring hospitalization and surgery. Inflammatory disorders may resolve upon sevelamer discontinuation. Treatment should be re-evaluated in patients who develop severe gastrointestinal symptoms.
Patient Counselling
Purpose of Therapy
Sevelamer helps control high phosphorus levels in the blood, which is a common problem when kidneys are no longer able to filter phosphorus effectively. By taking sevelamer with every meal, the medication traps phosphorus from food in the digestive tract and removes it from the body, preventing it from building up in the blood where it can damage bones and blood vessels.
How to Take
Take sevelamer with each meal — it only works when there is food (and therefore dietary phosphorus) in the stomach. Swallow tablets whole with water; do not crush or break them. For the powder form, mix the prescribed amount with water as directed, stir vigorously, and drink the entire preparation within 30 minutes. Never heat the powder or add it to hot foods or beverages. Follow the phosphorus-restricted diet prescribed by your renal dietitian.
Sources
- RENVELA (sevelamer carbonate) tablets and powder — Full Prescribing Information. Genzyme Corporation. Revised 06/2023. FDA LabelPrimary source for all dosing tables, contraindications, adverse reactions, drug interactions, and clinical pharmacology data.
- Sevelamer carbonate for oral suspension (generic) — FDA Label. FDA LabelConfirms generic availability and equivalent labeling for the powder formulation.
- Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245–252. doi:10.1046/j.1523-1755.2002.00434.xTreat to Goal trial (N=200): demonstrated that sevelamer slowed progression of coronary and aortic calcification compared to calcium-based binders, with equivalent phosphorus control.
- Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130–1137. doi:10.1038/sj.ki.5002466DCOR trial (N=2103): no significant overall mortality difference between sevelamer and calcium-based binders; secondary subgroup analysis suggested lower mortality in patients >65 years with sevelamer.
- Di Iorio B, Bellasi A, Russo D; INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7(3):487–493. doi:10.2215/CJN.03820411INDEPENDENT trial (N=212, stage 3–4 CKD outpatients not on dialysis): sevelamer associated with lower all-cause mortality compared to calcium carbonate over 36 months; pilot study requiring confirmation by larger trials.
- Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62(4):771–778. doi:10.1053/j.ajkd.2013.03.023INDEPENDENT-HD trial (N=466): sevelamer-treated incident HD patients had lower CV mortality, particularly from cardiac arrhythmias, compared to calcium carbonate over 24 months.
- Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68(4):1815–1824. doi:10.1111/j.1523-1755.2005.00600.xRIND study: in incident HD patients, those randomized to calcium-based binders had significantly more rapid progression of coronary artery calcification than those on sevelamer over 18 months.
- St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the DCOR trial. Am J Kidney Dis. 2008;51(3):445–454. doi:10.1053/j.ajkd.2007.12.002Intent-to-treat secondary analysis of DCOR using Medicare claims data; confirmed no overall mortality difference but suggested fewer hospitalizations and hospital days with sevelamer.
- KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD. Kidney Int Suppl. 2017;7(1):1–59. doi:10.1016/j.kisu.2017.04.001Current global guideline for CKD-MBD management, recommending phosphate-lowering treatment when hyperphosphatemia is progressive and suggesting limiting calcium-based binder use.
- Plone MA, Petersen JS, Rosenbaum DP, Burke SK. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet. 2002;41(7):517–523. doi:10.2165/00003088-200241070-00003¹&sup4;C mass balance study confirming zero systemic absorption of sevelamer, establishing the drug’s purely local GI mechanism of action.
- Patel L, Bernard LM, Elder GJ. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2016;11(2):232–244. doi:10.2215/CJN.06800615Meta-analysis of RCTs comparing non-calcium binders (primarily sevelamer) with calcium-based binders; found reduced all-cause mortality and less vascular calcification with non-calcium binders.
- Chue CD, Townend JN, Moody WE, et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol. 2013;24(5):842–852. doi:10.1681/ASN.2012070719Randomized, placebo-controlled trial in stage 3 CKD patients: sevelamer reduced FGF-23 and improved lipid profile but did not significantly alter LV mass, arterial stiffness, or endothelial function over 40 weeks.